Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insilico Medicine

http://insilico.com

Latest From Insilico Medicine

Big Tech's Growing Biopharma Prominence

If activity at the recent J.P. Morgan Healthcare Conference is an indication of what is up ahead, 2024 is set to be the year of big tech in biopharma. 

Market Intelligence Innovation

Biopharma Must Be Prepared For Era Of Quantum Computing

Quantum computing is both mysterious and prone to hype, but the reality of a quantum era is approaching and the benefits for biopharma could be enormous. Prepare ahead of time to gain a first mover advantage, say the experts. 

Innovation Strategy

Exelixis Adds Insilico Deal In Search Of Growth Beyond Cabometyx

After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.

Commercial Companies

Finance Watch: Q2 Saw Fewer, But Larger, Venture Capital Deals

Private Company Edition: Fewer biotech companies raised venture capital in the second quarter, but the amount of capital raised was on par with the first quarter. Also, former BMS R&D exec Rupert Vessey joined Flagship Pioneering, two new VC funds emerged and Septerna raised a $150m series B round.

Financing Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register